Table 3.
Type and schedules of adjuvant chemotherapy prescribed (n = 1095)
| Type of chemotherapy | N (%) |
|---|---|
| CMF-like |
100 (9.1) |
| · Anthracyclines alone (without Taxanes) |
534 (48.8) |
| · Anthracyclines plus Taxanes |
420 (38.4) |
| · Taxanes alone (without Anthracyclines) |
41 (3.7) |
| Type of Taxane |
|
| · Docetaxel |
359 (32.8) |
| · Paclitaxel |
102 (9.3) |
| Main chemotherapeutic schedules administered |
|
| · Oral classical CMF 6 cycles |
24 (2.2) |
| · CMF 6 cycles iv day 1 and 8 q28d |
53 (4.8) |
| · CMF 6 cycles iv day 1 q21d |
9 (0.8) |
| · CMF 3–4 cycles iv day 1 and 8 q28d |
11 (1.0) |
| · AC 4 cycles |
89 (8.1) |
| · AC 6 cycles |
27 (2.5) |
| · E90C 4 cycles |
56 (5.1) |
| · E75C 4 cycles |
9 (0.8) |
| · FE75C 6 cycles |
131 (12.0) |
| · FE90C 6 cycles |
95 (8.7) |
| · FE100C 6 cycles |
29 (2.6) |
| · FAC 6 cycles |
8 (0.7) |
| · Canadian CEF 6 cycles |
16 (1.5) |
| · Epidoxorubicin 4 cycles – CMF 4 cycles |
5 (0.5) |
| · AC 4 cycles – CMF 3 cycles |
15 (1.4) |
| · FEC 3 cycles - Docetaxel 3 cycles |
118 (10.8) |
| · AC/EC 4 cycles - Docetaxel 4 cycles |
127 (11.6) |
| · TAC 6 cycles + G-CSF |
29 (2.7) |
| · AC/EC 4 cycles - Paclitaxel q3wks 4 cycles |
39 (3.6) |
| · FEC/EC 4 cycles - weekly Paclitaxel x 12 |
43 (3.9) |
| · A/EP 4 cycles – CMF 4 cycles |
7 (0.6) |
| · ET 6 cycles |
12 (1.1) |
| · TC 4 cycles |
19 (1.7) |
| · TC 6 cycles |
8 (0.7) |
| · Others | 116 (10.6) |
C = Cyclophosphamide; M = Methotrexate; F = Fluorouracil; A = Doxorubicin; E = Epirubicin; P = Paclitaxel; T = Docetaxel.